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Abstract
The mechanism of membrane fusion by ‘‘class II’’ viral fusion proteins follows a pathway that involves large-scale domain
rearrangements of the envelope glycoprotein (E) and a transition from dimers to trimers. The rearrangement is believed to
proceed by an outward rotation of the E ectodomain after loss of the dimer interface, followed by a reassociation into
extended trimers. The ,55-aa-residue, membrane proximal ‘‘stem’’ can then zip up along domain II, bringing together the
transmembrane segments of the C-terminus and the fusion loops at the tip of domain II. We find that peptides derived from
the stem of dengue-virus E bind stem-less E trimer, which models a conformational intermediate. In vitro assays
demonstrate that these peptides specifically block viral fusion. The peptides inhibit infectivity with potency proportional to
their affinity for the conformational intermediate, even when free peptide is removed from a preincubated inoculum before
infecting cells. We conclude that peptides bind virions before attachment and are carried with virions into endosomes, the
compartment in which acidification initiates fusion. Binding depends on particle dynamics, as there is no inhibition of
infectivity if preincubation and separation are at 4uC rather than 37uC. We propose a two-step model for the mechanism of
fusion inhibition. Targeting a viral entry pathway can be an effective way to block infection. Our data, which support and
extend proposed mechanisms for how the E conformational change promotes membrane fusion, suggest strategies for
inhibiting flavivirus entry.
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Introduction
Membrane fusion is a critical step for infectious entry of
enveloped viruses into cells [1]. A viral ‘‘fusion protein’’ facilitates
this process, generally in response to molecular cues specific for the
cellular compartment in which viral penetration occurs. For
example, dengue and other flaviviruses penetrate from endosomes,
following uptake by clathrin-mediated endocytosis [2,3], and
proton binding is the immediate fusion trigger [4].
The flaviviruses are insect-borne agents with positive-strand
RNA genomes packaged into compact particles, about 500 A ˚ in
diameter [5]. Their fusion protein, known as E, is the principal
external protein of the virion. It is made as part of a polyprotein,
which includes a ‘‘chaperone’’ protein, designated prM (precursor
of M). Cleavage of prM during viral maturation releases most of its
ectodomain and promotes formation of a well-ordered lattice of 90
E dimers on the virion surface [6,7]. When the pH drops below
about 6.2, E undergoes a large-scale conformational rearrange-
ment that includes dissociation of the dimer and reconfiguration of
the subunits into trimers (Fig. 1A,B) [8]. At an intermediate stage
in this complex molecular reorganization, a hydrophobic ‘‘fusion
loop’’ at one end of the extended E subunit inserts into the outer
leaflet of the target membrane bilayer [9,10,11,12]. Further
rearrangement then draws together the fusion loop and the
transmembrane segment anchoring E in the viral membrane. The
latter step forces the two membranes together, allowing fusion to
ensue.
This molecular description of flavivirus fusion derives in part
from crystal structures of several flavivirus E proteins in
conformations corresponding to prefusion dimers and to postfu-
sion trimers (Fig. 1A) [9,11,12,13,14]. These structure determina-
tions were made possible by C-terminal truncation of the E
ectodomain, through proteolytic treatment or recombinant
expression, to increase protein solubility and biochemical stability
[15]. These soluble forms of E (‘‘sE’’) include only the first 395 of
the approximately 445 ectodomain residues; they lack a
membrane-proximal region called the ‘‘stem’’ (Fig. 1C) that is
substantially conserved among flaviviruses. Intermediate-resolu-
tion cryoEM reconstructions show that in the prefusion dimer, the
stem segment folds into a helix-loop-helix sandwiched between the
rest of the ectodomain and the membrane [7,16]. In the postfusion
conformation, it has been inferred that the stem extends along the
edge of domain II, which bears the fusion loop at its tip (Fig. 1)
[11].
In the postfusion conformation of E, the fusion loops and the C-
terminal transmembrane anchors of all three subunits cluster at
one end of the rearranged protein (Fig. 1B). The driving force for
pinching together of the two membranes appears to come from
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the base of the hairpin, and by the stem with domain II, as it
‘‘zips’’ up along domain II. A consequence of this picture is that
interfering with either of these interfaces – for example, by a
soluble form of domain III or of the stem – will probably prevent
viral fusion. A well-known precedent is T-20/entfuvirtide, a
peptide inhibitor of HIV-1 infectivity [17,18,19,20]. T-20 is a
soluble fragment of gp41 that blocks the analogous zipping-up step
in gp41 refolding. Kielian and co-workers have shown that soluble
dengue E-protein domain III can inhibit entry of dengue virus
bound at the cell surface when fusion is triggered by transient
acidification, and they have made similar observations for the
related alphavirus fusion protein, E1 [21]. The likely mechanism
involves binding of the soluble domain to the extended
intermediate structure, thereby aborting the internal fold-back.
One report also suggests that a stem peptide can inhibit dengue
virus infection in a conventional infectivity assay, but with no
mechanistic analysis [22]. The observation is puzzling, because we
might expect a site for specific stem-peptide binding to be present
only after induction of a conformational transition by the low pH
of an endosome and an externally applied peptide to be inactive
unless carried into the endosome by some non-specific process.
In the work reported here, we show that peptides derived from
the dengue E protein stem indeed bind the trimeric, postfusion sE
conformer, but not the prefusion dimer. The sequence specificity
of this interaction is consistent with our prediction, based on the
trimeric sE structure, that such peptides should be able to dock
against domain II. We also show that the same stem peptides can
inhibit viral infectivity by binding the virion at neutral pH before
cell attachment and, presumably, by accompanying the virus
particles into endosomes. Hydrophobic interactions between the
C-terminal segment of the peptide and the viral membrane
contribute to virion binding and hence to inhibiting infection;
sequence-specific contacts may have a role in initial binding, in
addition to their principal inhibitory contribution when internal-
ized peptide binds rearranging E protein, after the virus has
encountered a lowered pH.
Results
Binding of stem peptides with sE
The order of conformational changes in E outlined in the
Introduction suggests that stem peptides might bind the trimer-
clustered domain-II regions of sE. That is, because the entire stem
is missing from the sE fragment, the sE trimer in effect represents
an intermediate state in the conformational transition, just before
the stem zips up along domain II. Fig. 1C shows the stem
sequences from DV serotypes as well as the closely related West
Nile Virus (WNV) and illustrates their nearly complete conserva-
tion. We made a set of synthetic peptides, all based on the DV2
consensus sequence, for affinity measurements. The peptides were
conjugated to FITC at their N-termini, and their affinities for
prefusion sE dimer and postfusion sE trimer were measured with a
fluorescence polarization assay.
We produced the trimeric postfusion form of sE following the
protocol of Modis et al (2004), which derived in turn from earlier
work [23] on tick-borne encephalitis (TBE) virus. Acidification of
sE dimer in the presence of liposomes leads to dimer dissociation,
insertion of the fusion loop into the outer liposome leaflet, and
catalysis of trimer formation by the enforced alignment of
monomers on the membrane surface. The sE remains trimeric
after neutralization; it is soluble in the presence of non-ionic
detergents.
We measured binding isotherms by adding increasing amounts
of either the prefusion or the postfusion conformer of sE to a
constant concentration of FITC-tagged peptide. Dissociation
constants (Kd) were calculated as described in Methods. Peptide
DV2
419–447 binds selectively to the postfusion conformer of sE; a
scrambled version of DV2
419–447 (DV2
419–447(scram)), used as a
specificity control, binds neither conformer (Fig. 2A). Results from
this series of experiments are summarized in Figure 2B. Peptides
containing the C-terminal half of the dengue virus type 2 stem
bind the sE postfusion trimer, while those derived exclusively from
the N-terminal half do not. Peptide 419–447 (DV2
419–447) has the
lowest Kd (,150 nM), and we have chosen to use it for many of
the subsequent studies reported below.
We confirmed the specificity of stem peptides for the postfus-
ion sE conformer by showing that a biotinylated derivative of
DV2
419–447 stably associates with trimeric sE, using the ‘‘pull-
down’’ protocol described in Methods. As shown in Fig. S1,
biotinyl-DV2
419–447 associates tightly with sE trimer but not with sE
dimer. As a control for non-specific interaction of the biotinylated
peptide with a detergent-solubilized protein, we used an irrelevant
membrane protein (the mitochondrial uncoupling protein, UCP)
and found no evidence for any association (data not shown).
Stem peptides inhibit viral fusion
If peptide binding to sE trimer mimics an association of stem
with domain II during the fusion-promoting conformational
change, then the bound peptides should block the final ‘‘zipping-
up’’ step and thereby prevent fusion. We used two methods to
monitor directly the effects of stem-derived peptides on dengue-
virus fusion with liposomes. One is a trypsin susceptibility assay,
which detects exposure of the viral core protein to liposome-
encapsulated protease as a measure of complete membrane fusion
and content mixing. The other is a pyrene fluorescence assay that
has been validated in many published studies of alphaviruses and
flaviviruses as a sensitive measure of hemifusion, an obligatory
intermediate step in the merging of two bilayers [24,25,26].
For the content-mixing assay, liposomes encapsulating trypsin
were made by extrusion in the presence of the protease.
Unincorporated trypsin was removed by size exclusion chroma-
Author Summary
Enveloped viruses must overcome a succession of cellular
barriers before establishing infection. One obstacle is
fusion of viral and cellular membranes. Rearrangements of
proteins on the viral surface facilitate fusion and subse-
quent delivery of the viral genome into the cytosol. In this
study, we probed the fusion-promoting rearrangement of
the dengue-virus envelope (E) protein. Peptides derived
from the membrane proximal ‘‘stem’’ of E bind to a form of
recombinant E that represents a late-stage intermediate in
its low-pH triggered conformational change. The binding
mimics a key step in the fusion-promoting process. We
find that these stem peptides also inhibit viral infectivity,
with potency proportional to their affinity for E, and that
they do so by specifically blocking fusion. We provide
evidence that inhibition is a two-step process: an initial,
nonspecific interaction of the peptide with the viral
membrane, followed by specific binding to E, as the
protein undergoes conformational rearrangement. The
initial step explains how the virus can carry the peptide
into an endosome—a necessary step, because the binding
surface on E becomes available only after exposure to low
pH. This work extends the model of flavivirus fusion, and
suggests strategies for targeting viruses that penetrate
from endosomes.
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ed at 37uC at neutral and low pH, in the presence of DV2
419–447
or DV2
419–447(scram); reactions were back-neutralized and incubat-
ed for 1hr at 37uC. Fusion, triggered by exposure to low pH, will
deposit the viral core into the liposome interior, exposing the
capsid protein to protease. The results in Figure 3A show that in
the presence of DV2
419–447, there is no more capsid degradation
than in the pH 8.0 control, whereas DV2
419–447(scram) has no
protective effect with respect to the pH 5.5 treated reaction.
Complete lysis of the liposomes with TX100 demonstrates that
there is sufficient trypsin encapsulated to digest the capsid protein
completely. DV2
419–447 inhibits membrane fusion in this model
system at a step prior to content mixing.
For the pyrene fluorescence measurements, virus was grown in
medium supplemented with pyrene-hexadecanoic acid, which
incorporates into membrane lipids. The pyrene labels the tip of the
fatty-acid chain near the bilayer midplane; an excited fluorophore
in one leaflet can collide with an unexcited fluorophore in the
other leaflet, generating an excimer with an altered emission
spectrum [27]. Fusion with an unlabeled liposome dilutes the
pyrene labeled lipids at the hemifusion stage, leading to a decrease
in fluorescence at the wavelength of the excimer emission
maximum. The data in Fig. 3B show that addition of 1mM
DV2
419–447 substantially reduced the extent of hemifusion with
respect to the effects of DV2
419–447(scram) and DMSO as controls.
Effect of stem peptides on viral infectivity
To examine the effect of the stem peptides on dengue virus
infectivity, we infected cells in the presence of varying peptide
concentrations and then measured viral yield 24 hours post-
infection by a standard viral plaque assay (see Methods). Stock
solutions of peptides were made in DMSO, and the final DMSO
concentration was always less than 1% when the stock was diluted
into medium. Peptides derived from the C-terminal part of the
stem inhibit viral replication. As shown in Fig. 2, the extent of
inhibition correlates strongly with the affinity of the peptide for the
Figure 1. Conformational states of the dengue virus E protein and sequences of the membrane-proximal ‘‘stem’’. (A) Structure of E in
the dimeric conformation present on the virion surface prior to low-pH exposure. The view is tangential to the viral membrane (gray stripe). The sE
component (residues 1–395) of the ectodomain is in ribbon representation, with domains I, II, and III in red, yellow, and blue, respectively. The stem
(residues 396–447) is shown as a helix-loop-helix, modeled from a cryoEM reconstruction [7]. The transmembrane anchor is an a-helical hairpin. (B) E
in the trimeric conformation it adopts following a low-pH induced conformational change. Dashed lines indicate the likely position of the stem
segments. (C) Linear representation of the E polypeptide chain, illustrating the regions that fold into the structures shown in A and B. The stem is
shown ‘‘magnified’’, together with stem sequences from dengue serotypes 1–4 and from West Nile virus (WNV). The designations of ‘‘helix 1’’,
‘‘conserved region’’, and ‘‘helix 2’’ follow.
doi:10.1371/journal.ppat.1000851.g001
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ments. Peptides that include the entire ‘‘helix II’’ segment are
particularly active. DV2
413–447 and DV2
419–447 are the strongest
inhibitors; neither scrambled version, DV2
413–447(scram) or
DV2
419–447(scram), has any effect on viral titre.
Effect of order of addition
At what stage in the infectious cycle do stem peptides interfere
with viral replication? The results shown in Fig. 2 were obtained
from experiments in which peptide and virus were preincubated
before application of the inoculum to cells. Thus, the peptides
could associate with virions prior to adsorption of the latter to cells
and inhibit completion of the envelope protein conformational
transition after virion uptake into endosomes. Alternatively, it is
possible that the peptides concentrate in endosomes and associate
with virions only in a low-pH environment. Either explanation
appears to present a puzzle. At the 500 nM concentration
sufficient, in the case of the most effective peptides, to inhibit
viral yields, an early endosome of 1500 A ˚ diameter would be
expected to contain only 1–2 peptides in the absence of some
mechanism to concentrate the peptide. This number is probably
too small to inhibit viral entry, as estimates for the number of
antibodies required to neutralize dengue virus range from 20
upwards, and it is likely that at least the same number of peptides
would be needed [28,29]. Yet, the inhibitory activity of the
peptides correlates with their binding to sE trimer, and the trimer
transition should occur only after endosomal acidification. The
correlation also appears to rule out a third possibility – that the
peptides stimulate or inhibit a cell-signaling pathway, rather than
inhibiting infection through direct interaction with virions.
To resolve these apparent contradictions, we carried out a series
of order-of-addition experiments using either DV2
419–447 or
DV2
419–447(sol). The latter spans the same sequence (419–447),
but has an additional ‘‘solubility tag’’, of sequence RGKGR, at its
C-terminus. The hydrophobicity of the stem peptide causes it to
aggregate almost immediately upon dilution from DMSO into the
medium, decreasing its effective concentration as the incubation
proceeds (data not shown); the solubility tag reduces aggregation
and stabilizes the peptide concentration. Pre-incubation of BHK-
21 monolayers with 10 mM DV2
419–447 for various times, followed
by infection with DV2 at a multiplicity of infection (MOI) 1 after
washing the cells free of the peptide, did not affect the viral yield
(data not shown). Thus, the peptide has no lasting effect on the
capacity of the cells to support viral replication. Preincubation of
virus with peptide DV2
419–447 for various times prior to
application to the monolayer leads to the same inhibition of
infectivity observed when the two are mixed and applied
immediately (Fig. 4A). Adding peptide at the end of the 1 hr
interval used for the infection had a small inhibitory effect,
suggesting the presence of some adsorbed but not yet endocytosed
particles, whereas adding peptide 2 hr after application of the virus
had no effect at all. We conclude that inhibition of infectivity
results from a direct interaction of the peptide with virions and
that the virion-bound peptide blocks an early step in infection.
In the experiments of Fig. 4, excess peptide was present during
the incubation of virus and cells. Rapid passage of the virus
through a short size-exclusion matrix, to remove excess peptide
prior to application of the inoculum to the monolayer, did not
reduce the extent of inhibition relative to a control passed similarly
through the matrix but with no added peptide (Fig. 4B). We
verified that the spin columns used for this treatment were effective
in removing unbound peptide by showing that no inhibitory
activity was present in the flow-through fraction after applying a
10 mM peptide solution (but no virus) to the column. Thus,
peptide appears either to associate tightly with virions or to induce
an irreversible, inactivating effect. Experiments described below
rule out the latter interpretation.
Reversibility of stem peptide inhibition
The experimental results in Fig. 4C show that inhibition of
infectivity by stem peptides is reversible. We preincubated a viral
inoculum with DV
419–447 at 37uC, then added liposomes in
Figure 2. Binding and affinities of stem-derived peptides with DV2 sE(1–395) and inhibition of DV2 infectivity. (A) Binding of a
representative stem-peptide, DV2
419–447, and of a peptide with the same composition but a scrambled amino-acid sequence, determined by
fluorescence anisotropy. The fraction bound is plotted as a function of sE protein concentration (in mM). sE2 and sE3 refer to dimer and trimer,
respectively. Trimer-binding curves were corrected for low levels of binding to the UDM present in the sE3 preparations. (B) The dissociation constants
for various stem peptides were estimated by the concentration of half-maximal change in fluorescence polarization (FP IC50), as described in
Methods. The effect on viral infectivity is shown as ‘‘IC90’’, the concentration of peptide that reduced viral yield (of DV2 on BHK cells) to 10% of the
control. N.B., no binding; N.A., no activity. Each FP IC50 is an average of at least three independent experiments, each done in triplicate. Each IC90 is
from an assay set up in duplicate and plaqued in triplicate.
doi:10.1371/journal.ppat.1000851.g002
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approaching the control by adding a suitable excess of liposomes,
into which the hydrophobic peptide could partition. The
reversibility of inhibition by stem peptides suggests that non-
specific membrane interactions may dominate the initial associ-
ation of peptide and virion and that this sequestration may
concentrate the peptide in the viral membrane for rapid
association during the short lifetime of the E-protein fusion
intermediate.
Effect of temperature
Together with the observation that stem peptides bind sE in its
rearranged, trimeric conformation, but not the sE dimer, the data
in the preceding section suggest that the peptide gains access to
sites, either on domain II or on the viral membrane, that are
occluded in the equilibrium structure deduced by fitting the dimer
model into cryoEM reconstructions [7]. Indeed, when we carried
out the peptide-virion incubations at 4uC rather than 37uC,
followed by quick warming and immediate application to the
BHK-21 cell monolayer, we found little or no effect on viral titre
(Fig. 5A). The results suggest that dynamics of the virion surface
permit access to transiently exposed sites on E, on the membrane,
or on both.
Direct detection of peptide association with virions
We examined the interaction of stem peptides and virions by
incubating biotinyl-DV2
419–447 with virions at 37uC for 45 min-
utes and then adding streptavidin resin (blocked with 10% fetal
bovine serum to minimize non-specific association) to bind the
peptide and any associated virus, which we detected by
immunoblotting as shown in Fig. 5B. Binding of virions was
efficient at pH 8, well above the pH threshold for fusion. As the
concentration of peptide increased, we could detect increasing
amounts of virus in the streptavidin eluate. Incubation of the virus
with biotinyl-peptide at 4uC resulted in a noticeably lower yield of
retained virions, consistent with the neutralization experiments
(Fig. 5B).
To confirm association of stem peptides with virions we used the
fluorescence properties of pyrene labeled virions as a direct
measure of membrane interaction. We observed that addition of
DV2
419–447 produces a concentration dependent loss in excimer
intensity (Fig. 6). We interpret this effect as a measure of
interaction of the peptide with the bilayer. Membrane binding
of stem peptides will decrease lipid mobility and hence decrease
the likelihood of excimer formation. Consistent with this
interpretation is the observation that DV2
419–447(scram), which is
as hydrophobic as the unscrambled peptide, also reduces the
Figure 3. Inhibition of fusion of virus and liposomes. (A) Effect on fusion-pore formation (content mixing) of preincubating virions with
DV2
419–447 or DV2
419–447(scram). Virions and peptides were incubated with liposomes encapsulating trypsin and acidified to pH=5.5. Following back-
neutralization and incubation for 1hr at 37C, samples were prepared for SDS-PAGE by TCA precipitation and immunoblotted with anti-C antibody.
Fusion leads to exposure of capsid protein to trypsin and loss of the corresponding band. (B) Effect on the hemifusion step of preincubating pyrene-
labeled virions with DV2
419–447 or DV2
419–447(scram). Hemifusion was measured by the decrease in pyrene excimer intensity when virions were acidified
to pH=5.5 in the presence of liposomes. Loss of excimer fluorescence following dissolution of the viral membrane by TX100 was taken as 100%. Data
represent three independent experiments.
doi:10.1371/journal.ppat.1000851.g003
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amphipathicity in the scrambled peptide may account for the
higher concentration required to achieve the same effect on the
pyrene excimer as with wild-type peptide.
At the respective concentrations at which WT and scrambled
peptides decrease the excimer intensity by 20%, the former
decreases viral titre by 90%, while the latter has no effect. This
comparison shows that loss of excimer signal is not due to a
Figure 4. Inhibition and reversibility of viral infectivity by DV2
419–447. (A) Influence of the time of peptide addition on viral yield. DV2
419–447
(or DMSO carrier, for the control) was added to virus at 37uC, 45 minutes (preincubation) or immediately (coinfection) before applying the inoculum
to cells, or at various time points postinfection (as shown by the time ramp). For the 09 time point, peptide was added promptly after adding the
inoculum. (B) Effect of separating peptide and virus prior to infection. DV2
419–447 (10 mM) was preincubated with virus for 159 or 459 at 37*C, and
unbound peptide was removed by rapid passage of the inoculum through a size-exclusion spin-column prior to addition to cells. Passage of virus
(plus DMSO carrier) through the column reduced titre by about 10-fold. The flow-through fraction (F.T.) of medium plus peptide had no inhibitory
effect on virus added subsequently, consistent with retention of all unbound peptide by the matrix. (C) Reversibility of stem peptide inhibition. Viral
inoculum was preincubated with DV2
419–447 for 109 at 37C. Liposomes were then added to the peptide:inoculum, in the molar excess of lipid
molecules to peptides shown and incubated for an additional 459. The inoculum was added to cells and harvested 24hrs later. An inoculum
preincubated with liposomes alone has no loss in viral titre.
doi:10.1371/journal.ppat.1000851.g004
Peptide Inhibitors of Dengue-Virus Entry
PLoS Pathogens | www.plospathogens.org 6 April 2010 | Volume 6 | Issue 4 | e1000851generalized membrane disruption that would inactivate the virus.
(Even at saturating concentrations, the peptides do not eliminate
excimer fluorescence completely, which we can do by adding
TritonX-100.) The comparison also shows that association of a
peptide with the membrane, as monitored by loss of excimer
signal, is not sufficient for neutralization of infectivity. Membrane
association appears to be necessary, however, as indicated by
comparison of peptides DV2
419–447 and DV2
419–440 (Fig. 2). The
latter lacks the hydrophobic segment between residues 441 and
447, but it binds soluble E trimer as tightly as does the former
(Fig. 2). Only at concentrations at which the shorter peptide
reduces the pyrene excimer intensity does it also neutralize (Fig. 2A
and B). These results also suggest that in the conformation E
reaches when fusion is complete, amino-acid residues in its stem
may bind along domain II only about as far as 440. On a mature
virion, residues between 441 and the transmembrane anchor
probably interact with the viral membrane; following fusion, they
may interact with the fused bilayers.
Discussion
We have found that peptides derived from the membrane
proximal region of the dengue virus E protein bind specifically to
the postfusion conformer of sE, which is a model for a fusion
intermediate. These peptides also inhibit viral infectivity – an
initially surprising observation because transition of E to its
postfusion conformation occurs in the sequestered environment of
an endosome. We have shown that the inhibition results from
direct interaction of the peptides with virions at neutral pH and
hence that the virus carries the peptide with it into the cell. The
peptides do not associate with virions at 4uC, suggesting that
binding depends on dynamic properties of the viral envelope. We
have further shown, using a liposome fusion assay, that the stem-
derived peptides inhibit viral fusion at a step prior to hemifusion
and fusion-pore formation.
How do these stem peptides inhibit fusion if their specific
binding sites are not exposed until acidification in an endosome?
Figure 5. Temperature dependence of peptide-virus interaction. (A) Inhibition of infectivity after incubating virus with DV2
419–447 at various
temperatures, as indicated. RT, room temperature. (B) Association of biotinyl-DV2
419–447 (DV2
B419–447) with purified dengue virions at 4uC and 37uC
(see Methods).
doi:10.1371/journal.ppat.1000851.g005
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sites as the E protein fluctuates among an ensemble of
conformations. A similar explanation has been offered to explain
neutralization of dengue virus by antibodies for which the epitopes
are blocked (or partly blocked) on the virion as modeled from the
cryoEM structure [30]. The antibodies can trap a small fluctuation
of the protein from its equilibrium conformation. The absence of
peptide binding to dengue virions at low temperature is consistent
with this type of model. Nonetheless, it seems unlikely that E could
spontaneously fluctuate at neutral pH toward a conformation close
to that of the postfusion trimer (the excursion of the domains and
the rearrangement of the E protein are too extensive), and to
consider a fluctuation-binding model, it is probably necessary to
assume that the peptide associates with a single domain II, rather
than with two that are clustered with each other as in the trimer. A
small fluctuation could readily make an edge of domain II
accessible to peptide: we know domain II to be hinged with respect
to domain I and to adopt somewhat different hinge angles in
different crystal forms of the sE dimer, suggesting a potential
source of conformational heterogeneity [31]. Residual, uncleaved
prM, which is present to varying degrees in most dengue inocula,
is also likely to cause perturbations in the packing of E dimers on
the virion surface [6,32]. The association of prM with E tilts the
latter outward from the particle surface, and we would expect that
a small number of prM-E heterodimers would introduce
dislocations and local disorder into the otherwise tightly packed
lattice of E dimers covering the virion.
The results of our membrane-fusion assays with pyrene-labeled
virus particles suggest an alternative, two-step model: step 1 is an
initial hydrophobic association of peptide and viral membrane,
and step 2 is a specific association with E during the low-pH
triggered conformational transition (Fig. 7). Even a modest
fluctuation of the closely packed E protein on the viral surface
would give an exogenous peptide access to the underlying
membrane bilayer, of which about two-thirds is free of intimate
protein contacts [7]. A peptide that could associate with the
membrane, e.g., as an amphipathic helix, would be carried with
the virus particle into an endosome and would be available to
‘‘spring into place’’ upon transient exposure of its site on domain
II, thereby blocking the fusion-promoting zipping-up of the E-
protein stem. Only peptides with the appropriate sequence would
be effective, consistent with the properties of the DV2
419–447(scram)
peptide, which binds well to virions, but not to E trimer, and has
no effect on viral infectivity. The two-step model is also consistent
with the sequence dependence of peptide binding as measured by
the effect of peptides on the intensity of the pyrene excimer in
Fig. 6 and with the requirements for trimer binding in vitro as
detected by fluorescence polarization (Fig. 2).
The last seven residues of DV2
419–447 appear to be important
for inhibitory activity. This membrane-proximal segment is the
most uniformly hydrophobic sequence in the stem. Residues 441–
447 contribute substantially to the neutralizing potency of the
peptide (compare peptides in Fig. 2) but not to its affinity for the sE
trimer. Moreover, reducing their hydrophobicity by substituting
the corresponding residues from WNV greatly reduces inhibition
of infectivity without affecting trimer binding (data not shown).
Thus, these residues might be particularly important contributors
to step 1 of the two-step model outlined above. If so, some specific
peptide-protein contacts might occur in concert with peptide-lipid
association. That is, residues 441–447, which do not contribute to
E-protein binding, could associate with the membrane, while some
part of the rest of the peptide made contact with its site on E,
exposed by fluctuation or disorder as suggested in the single-step
model. According to this combination of the two models above,
non-specific membrane interactions and specific domain-II
interactions would jointly recruit the peptides, rather than
Figure 6. Stem peptides interact with the dengue virus membrane. Decrease in pyrene-excimer fluorescence intensity, as a function of the
concentration of stem peptide added to pyrene-labeled virions, normalized to its complete loss upon addition of TX100.
doi:10.1371/journal.ppat.1000851.g006
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could then form upon full exposure of domain II during the
low-pH induced conformational transition.
Our data suggest strategies, which might otherwise have seemed
unlikely, for inhibiting entry of viruses that fuse in endosomes or
other internal compartments. Peptides from the membrane-
proximal region of the HIV gp41 ectodomain are effective
inhibitors of HIV entry, but fusion at the cell surface has made the
transient intermediate in envelope refolding seem a more plausible
target for HIV than for viruses with envelopes that expose an
extended intermediate only after internalization [19,20]. If
peptides or small molecules can be concentrated in a viral
membrane by tethering to a hydrophobic ‘‘tail’’, then it may be
possible to enhance the potency of inhibitors identified by a simple
binding assay such as the one we have used here.
Materials and Methods
Peptide synthesis
Peptides were synthesized with standard Fmoc chemistry on
ABI 431 Peptide Synthesizers at the Tufts University Core Facility
(Boston, MA). They were purified using reverse phase HPLC and
analyzed by mass spectrometry. Biotin and fluorescein-isothiocy-
anate (FITC) were conjugated to the N-terminus of the peptides
via a beta-alanine linker.
Liposomes
Liposomes [1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC): 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine
(POPE) (Avanti Polar Lipids) and cholesterol (Sigma-Aldrich) at
1:1:2 molar ratio in TAN buffer (20mM triethanolamine, 100mM
NaCl, pH 8.0)] were prepared by freeze-thaw extrusion through a
0.2 m filter as described previously [11]. Liposomes were used
within 2 days of preparation.
Preparation of sE trimers
The postfusion sE trimer was produced as described [11]. Briefly,
purified sE (Hawai’i Biotech) was incubated in the presence of
liposomesfor15 minsat37C,acidifiedwithMES orsodiumacetate
to a final pH of 5.5, incubated for an additional 30 mins at 37C and
at then at room temperature 1hr. Liposomes were solubilized with
n-octyl-b-D-glucoside (b-OG) and n-undecyl-maltopyranoside
(UDM). The solution was applied to a MonoS column (GE
Healthcare) in 25mM sodium citrate pH 5.2, 100mM NaCl, 4mM
UDM. sE trimer was eluted with a 1–1.5M NaCl step gradient and
further purified by size-exclusion chromatography on Superdex 200
(GE Healthcare) in 10mM TEA, 80mM NaCl and 0.7mM UDM.
Protein was dialyzed extensively using a 50-kDa molecular-weight
cutoff membrane (Spectrapor).
Fluorescence polarization
Binding experiments were carried out in Corning, low-volume
384 well microplates and analyzed in a PerkinElmer EnVisions
instrument (excitation wavelength, 485nm; emission wavelength,
535 nm). Stock concentrations of FITC-conjugated peptide were
made in DMSO and dissolved in assay buffer immediately before
use. Increasing concentrations of protein were used with a
constant, 20nM, concentration of peptide. Each well contained a
final volume of 20uL in TAN buffer. Plates were incubated at 4C
and data collected at 3 and 24 hours. Kd were estimated as the
concentration of protein with half-maximal increase in fluores-
cence polarization.
Biotin-streptavidin pull-down
Recombinant sE (5mg) or purified virions (2.5mg) were incubated
with biotinylated DV2
419–447 or DV2
419–447(scram) for 15 mins at
37uC. Streptavidin resin was incubated with 10% FBS at room
temperature for 1 hr prior to use, to reduce non-specific binding.
Protein and peptide mixtures were incubated with the treated resin
for 30 mins at 4uC with constant rotation. Reactions were spun at
14,000rpm in a microcentrifuge at 4C for 10 mins, the
supernatant aspirated, and the resin resuspended in 1 mL TAN
buffer and spun again for 15 mins. After six further washes in
1 mL TAN buffer, the resin was resuspended in SDS-loading
buffer, incubated for 15 mins at 100uC, and analyzed by SDS-
PAGE (10 or 15%, precast gels, Biorad). Protein bands were
Figure 7. Model for inhibition of dengue-virus fusion by stem-derived peptides. The stem peptide (magenta-dotted line) may bind in an
initial, protein-specific interaction to the edge of E, domain II, dynamically exposed at neutral pH. The yellow arrow shows a likely fluctuation in the
orientation of domain II, based on observed variation in the domain I-domain II hinge angle. Alternatively, a two-step model may obtain, in which the
stem peptide has an initial non-specific membrane interaction that anchors it through its C-terminus in the viral membrane (magenta-solid line) at
neutral pH. As fusion within an endosome proceeds toward the final ‘‘zipping up’’ step, with collapse of the extended intermediate, the peptide,
carried into the endosome by association with the viral membrane, could then make a high-affinity, protein-specific interaction with trimer-clustered
domain II, blocking hemifusion and pore formation by preventing close approach of the fusion peptide and transmembrane anchor (later images of
panel).
doi:10.1371/journal.ppat.1000851.g007
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indicated. Immunoblots were visualized by chemiluminescence
(ECL reagents, Pierce).
Trypsin sensitivity (content-mixing) assay
Liposomes were prepared as above, after addition of trypsin at
10 mg/ml to the lipids [33]. Unencapsulated trypsin was removed
by passage of the suspension through a Superdex 200 gel filtration
column (GE Healthcare). Purified virions (0.5–1 mg) were added to
trypsin-containing liposomes in a final working volume of 200mL
in TAN buffer. DV2 stem peptides were added at appropriate
concentrations from DMSO stocks. Reactions were incubated at
37uC for 15 mins, acidified with sodium acetate pretitrated to
reach a final pH of 5.5, and further incubated at 37uC for 30 mins.
Reactions were neutralized with 1M TEA to a final pH of 8.0.
Trypsin digestion was allowed to proceed for 1hr at 37uC. Aliquots
of the reaction were resuspended in SDS-loading buffer, incubated
for 20 mins at 100uC, and analyzed by SDS-PAGE followed by
immunoblotting with an anti-dengue capsid antibody.
Pyrene fluorescence fusion assay
Dengue virions containing v-pyrene fatty acids in some of their
phospholipids were produced. Briefly, BHK-21 cells were grown
in the presence of 15 mg/ml of pyrene-hexadecanoic acid
(Invitrogen) prior to infection with dengue virus serotype 2. Virus
was harvested 24 hrs postinfection and purified as described
above. Pyrene labeled virions were added to a quartz cuvette in
the presence of 200 mM liposomes (prepared as described above)
and brought to final volume with TAN buffer, pH 8.0. Reactions
were continuously monitored with 343 nm and 470 nm as the
excitation and emission wavelengths, respectively. Reactions were
acidified with MES, pretitrated to yield a final pH of 5.5.
Reactions were stopped by addition of 0.1% TritonX-100 to cause
complete dilution of the probe. The fusion index was calculated as
a percent of the loss of excimer intensity upon addition of
TritonX-100.
Cells and viruses
C6/36 cells were maintained in L-15 medium supplemented
with 10% fetal bovine serum as well as penicillin, streptomycin,
and ketonocazole (Invitrogen). For viral plaque assays, BHK-21
cells were seeded (5610
4 cells/well) in 24-well, treated tissue-
culture plates in a-MEM supplemented with HEPES, pen/strep
antibiotics, and 5% Fetal Bovine Serum (FBS). Cells were plated
,12 hrs before use and stored at 37C with 5% CO2.
Dengue virus serotype 2 New Guinea Clone (NGC) was
adsorbed to confluent layers of C6/36 cells for 1hr at 25uC with
rocking every 15 mins. L-15 medium (Mediatech) was added, and
cells were incubated at 25uC for 7 days until syncytia formation
was observed. The supernatant was clarified by centrifugation at
1000 RPM for 15 mins at 4uC. Aliquots were stored at 280uC.
Plaque assay
BHK-21 cells were seeded as described above. Aliquots from
infections were thawed at 37uC in a water bath. 10 fold dilutions in
Earle’s balanced salt solution (EBSS) were prepared in 96-well
plates by transferring 20 ml from one well to 180ml EBSS in the
next. 100 ml of each dilution were added to cells. Plates were
incubated for 1hr at 37uC and rocked every 15 mins. Unadsorbed
virus was removed by two washes with 1 ml PBS, after which 1ml
of a-MEM supplemented with carboxymethylcellulose (CMC),
pen/strep antibiotics, HEPES and 2%FBS, was added to each well
and incubated at 37uC for 4 days. The CMC overlay was
aspirated, and cells were washed 26 with 1mL PBS and stained
with crystal violet. Plates were washed with water to remove excess
crystal violet and dried overnight.
Plaque reduction inhibition assays
Cell supernatant was diluted in EBSS to a stock concentration
that would allow for infection at MOI of 1, based on 50,000
seeded cells. Peptides (or carrier) were added to the inoculum as
indicated for each experiment. Cells were infected for 1hr at 37uC
with gentle rocking every 15 mins. Virus (or virus:peptide
mixtures) were washed from cells with 1mL of PBS (26) and
overlay medium (a-MEM supplemented with HEPES, pen/strep
antibiotics and 2% FBS) added. Plates were incubated at 37uC for
24 hrs. Aliquots of the supernatant were withdrawn and stored at
280uC for plaque assay as described above.
For experiments to remove excess peptide, virus and peptide
were incubated at 37uC for 15 mins and passed over a small G-50
desalting column (GE Healthcare) equilibrated with EBSS. 100 ml
of the flow-through (which contained the virus:peptide complexes)
were used to infect 5610
4 BHK cells (MOI ,1) in 24-well plates
for 1hr at 37uC. Cells were washed 26 with PBS and overlayed
with a-MEM medium supplemented with 2.0% FBS. Superna-
tants were harvested 24 hrs later and analyzed by the plaque assay
described above.
Virus purification
Virus was precipitated from C6/36 infected cell supernatant by
addition of polyethylene glycol molecular weight 8000 (PEG8000,
Sigma-Aldrich) and incubation overnight at 4uC with constant
mixing. The virus was then pelleted by centrifugation for 30 mins
at 10,0006g, 4uC, and the pellet was resuspended in TAN buffer
and clarified by centrifugation at 5,0006g for 20 mins at 4uC.
Virions were further purified on a 10% and 40% potassium
tartrate with 7.5 and 30% glycerol, step gradient and centrifuged
at 146,0006g for 2.5 hrs at 4uC. The gradient was harvested into
10 fractions and immunoblotted with antibodies against E
(obtained from ATCC: [34]) or C (supplied by Dr. J.G. Asakov:
[35]) to locate the virus. Those fractions were then pooled,
concentrated and cleared of potassium tartrate and glycerol by
exchange into TAN buffer using a 100K molecular weight cut-off
concentrator (Amicon). Virus concentration was determined with
the BCA assay (Pierce). Purified virus was stored at 4uC and used
within one week of purification.
Supporting Information
Figure S1 Binding of stem-derived peptides with DV2 sE(1–
395). Binding of sE to streptavidin beads in the presence of
biotinylated DV2
419–447. Peptide was added at the concentration
shown to 2.5 mg sE dimer or trimer.
Found at: doi:10.1371/journal.ppat.1000851.s001 (0.68 MB
DOC)
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